E7974 是一种选择性 α-微管蛋白 (α-tubulin) 抑制剂(IC50 为 3.9 μM),可破坏有丝分裂纺锤体形成、诱导 G2-M 期细胞周期阻滞、启动细胞凋亡 (apoptosis)、激活 caspase-3 并诱导聚腺苷二磷酸核糖聚合酶裂解,同时可缩小小鼠模型中的脉络膜新生血管面积,负载于修饰胶束中时发挥抗血管生成作用,可用于癌症和脉络膜新生血管的相关研究。
产品编号: MS-F34893 CAS No.: 610787-07-0 分子式: C24H43N3O4 分子量: 437.63
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

E7974 是一种选择性 α-微管蛋白 (α-tubulin) 抑制剂(IC50 为 3.9 μM),可破坏有丝分裂纺锤体形成、诱导 G2-M 期细胞周期阻滞、启动细胞凋亡 (apoptosis)、激活 caspase-3 并诱导聚腺苷二磷酸核糖聚合酶裂解,同时可缩小小鼠模型中的脉络膜新生血管面积,负载于修饰胶束中时发挥抗血管生成作用,可用于癌症和脉络膜新生血管的相关研究。

生物实验数据

生物活性 E7974 is a selective α-tubulin inhibitor with an IC50 of 3.9 μM that disrupts mitotic spindle formation, induces G2-M cell cycle arrest, initiates apoptosis, activates caspase-3, and induces poly(ADP-ribose) polymerase cleavage, while also reducing choroidal neovascularization area in mouse models and exerting anti-angiogenic effects when loaded in modified micelles, making it applicable for research on cancer and choroidal neovascularization.
IC50 & Target

α-Tubulin

3.9 μM (IC50)

体外研究
(In Vitro)

E7974 (300 nM; 0-24 h) 可在人组织细胞淋巴瘤 U-937 细胞中诱导持续的 G2-M 期有丝分裂阻滞,进而引发以处理后 8 h 开始出现亚二倍体细胞形成为特征的细胞凋亡。
E7974 (300 nM; 1-13 h) 可在人组织细胞淋巴瘤 U-937 细胞中诱导最大程度的有丝分裂阻滞。
E7974 (300 nM; 0-24 h) 可诱导人组织细胞淋巴瘤 U-937 细胞发生凋亡,这一点可从处理后 6 h 起始的 procaspase-3 和 PARP 剪切得到证实。
E7974 (19.5-65 nM; 18 h) 可破坏 DU 145 人前列腺癌细胞的有丝分裂纺锤体形成并诱导有丝分裂停滞,在较高浓度下还会降低非分裂细胞中的微管密度。
E7974 (300 nM) 可诱导人前列腺癌细胞 DU 145 发生 G2-M 期有丝分裂阻滞及后续的细胞凋亡。

Cell Cycle Analysis

Cell Line: U-937 human histiocytic lymphoma cells
Concentration: 300 nM
Incubation Time: 0-24 h
Result: Induced a G2-M block beginning as early as 4 h of treatment, with the G1 phase completely depleted by 10 h.
Showed an increasing hypodiploid cell population, indicative of apoptosis, evident at 8 h, and nearly all cells were hypodiploid after 24 h.
Demonstrated approximately 80% of U-937 cells in the G2-M peak after 14 h of treatment were positive for phospho-histone H3, confirming mitotic arrest, and close to half of hypodiploid cells were also phospho-histone H3 positive.

Cell Cycle Analysis

Cell Line: U-937 human histiocytic lymphoma cells
Concentration: 300 nM
Incubation Time: 0, 10, 30, 45, 60 min, followed by 12 h incubation in drug-free medium
Result: Showed percentages of cells in G2-M after 12 h in drug-free medium were 15% (0 min exposure), 35% (10 min), 47% (30 min), 62% (45 min), and 71% (60 min).
Demonstrated a 60-minute exposure to E7974 was sufficient to induce near-complete mitotic arrest 12 h later.

Western Blot Analysis

Cell Line: U-937 human histiocytic lymphoma cells
Concentration: 300 nM
Incubation Time: 0-24 h
Result: Induced proteolytic cleavage of procaspase-3 (generating active caspase-3) and PARP (generating an 84 kDa cleaved fragment) after 6 h of exposure, correlating with the appearance of hypodiploid cells detected by flow cytometry.

Immunofluorescence

Cell Line: DU 145 human prostate cancer cells
Concentration: 19.5 nM, 65 nM
Incubation Time: 18 h
Result: Induced marked increases in numbers of mitotic cells (positive for phospho-histone H3), with disorganized, tangled arrays of short microtubule fragments forming abnormal mitotic spindles; chromosomes failed to align at the cell center, indicating arrest in late prophase or prometaphase.
Showed at the higher concentration (65 nmol/L), nonmitotic cells had marked decreases in microtubule density.
体内研究
(In Vivo)

E7974 (0.2-20 µM;玻璃体内给药;激光凝固术后立即单次给药) 单独以 20 µM 玻璃体内给药时,可显著减小小鼠激光诱导脉络膜新生血管 (CNV) 模型中的 CNV 面积。

Animal Model: C57BL/6J mice (male, adult, laser-induced choroidal neovascularization)
Dosage: 0.2 µM; 2 µM; 20 µM
Administration: intravitreal; single dose immediately after laser coagulation
Result: Did not significantly reduce CNV area compared to vehicle-treated eyes (0.2 µM standalone).
Did not significantly reduce CNV area compared to vehicle-treated eyes (2 µM standalone).
Caused a significant reduction in CNV area compared to vehicle-treated eyes (20 µM standalone).

化学信息

分子量 437.63
分子式 C24H43N3O4
CAS No. 610787-07-0

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础